NovoCure Limited
NASDAQ:NVCRMedical - Instruments & Supplies
-$3.51 today
- Market cap
- $1.25B
- Beta
- 0.92
- P/E (TTM)
- -9.5
- EPS (TTM)
- -$1.52
Volume 1.41M
Average 1.52M
NVCR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
NovoCure LimitedNASDAQ: NVCR
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $63.01M rose 113.2% year over year, ahead of the -23.8% change in trailing-twelve-month stock-based compensation.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 26.4 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +113.2% holds above the trailing-twelve-month pace of -23.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 160.04M | +38.4% |
| FY2023 | 2023-12-31 | 115.61M | +8.1% |
| FY2022 | 2022-12-31 | 106.96M | +12.7% |
| FY2021 | 2021-12-31 | 94.9M | — |
Stock-Based Compensation vs competitors
How NVCR compares with its peers on the latest reported figures
- NVCR's LTM Mar 2026 stock-based compensation of $118.47M is the largest of the 4 companies compared; the peer median is $17.47M.
- Its year-over-year change of -23.8% is the lowest of 4, against a peer median of +3.6%.
- Stock-based compensation amounts to 17.6% of revenue for NVCR, versus a peer median of 24.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $118.47M | -23.8% | — | 17.6% | |
| LTM Mar 2026 | $22.32M | +63.1% | +45.0% | 24.7% | |
| LTM Jun 2026 | $17.47M | -15.4% | +60.5% | 1474.4% | |
| LTM Mar 2026 | $10.74M | +3.6% | +9.9% | 10.8% | |
| Peer median (excluding NVCR) | $17.47M | +3.6% | +45.0% | 24.7% | |
Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.35M) | (92.53M) | (207.04M) | (168.63M) | (136.23M) |
| Depreciation & Amortization | 10.25M | 10.62M | 10.97M | (14.41M) | 14.65M |
| Deferred Income Tax | 3.88M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 94.9M | 106.96M | 115.61M | 160.04M | 0 |
| Change in Working Capital | 29.07M | 11.8M | 29.56M | (4.3M) | (15.13M) |
| Accounts Receivables | 5.27M | 2.55M | 29.41M | (26.36M) | (38.94M) |
| Inventory | 2.48M | (4.34M) | (8.92M) | 2.57M | (5.67M) |
| Accounts Payables | 27.78M | 14.26M | 14.87M | 19.11M | 18.96M |
| Other Working Capital | (6.46M) | (666K) | (5.8M) | 384K | 10.52M |
| Other Non-Cash Items | 3.01M | (6.05M) | (22.43M) | 932K | 87.67M |
| Operating Cash Flow | 82.76M | 30.79M | (73.34M) | (26.37M) | (49.03M) |
| Capital Expenditures | (24.17M) | (21.36M) | (27.09M) | (42.86M) | (26.65M) |
| Acquisitions (Net) | 120.66M | 118.6M | 0 | 0 | 0 |
| Purchases of Investments | (1.08B) | (1.3B) | (1B) | (875.39M) | (821.08M) |
| Sales of Investments | 958M | 1.18B | 1.21B | 778M | 1.29B |
| Other Investing Activities | (120.66M) | (118.6M) | 0 | 0 | 0 |
| Investing Cash Flow | (144.83M) | (139.96M) | 184.15M | (140.24M) | 437.28M |
| Debt Repayment | (26K) | (28K) | (10K) | 84.01M | (460.97M) |
| Common Stock Issued | 4.55M | 5.22M | 4.42M | 4.15M | 9.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 21.18M | 10.3M | 11.38M | 2.16M | (146K) |
| Financing Cash Flow | 25.7M | 15.49M | 15.79M | 90.32M | (451.34M) |
| Effect of Forex Changes | (188K) | (97K) | 131K | (174K) | 394K |
| Net Change in Cash | (36.56M) | (93.78M) | 126.73M | (76.47M) | (62.7M) |
| Free Cash Flow | 58.59M | 9.43M | (100.43M) | (69.22M) | (75.68M) |
NovoCure Limited
NASDAQ:NVCR
Intrinsic Alpha fair value
Locked
Current Price
$10.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.